Pharmacological management of hypertension in the elderly and frail populations

References

• Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1–25.
   PubMed Web of Science ®Google Scholar
• Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet. 2014;383(9932):1899–1911.
   PubMed Web of Science ®Google Scholar
• Fryar CD, Ostchega Y, Hales CM, et al. Hypertension prevalence and control among adults: United States, 2015–2016. NCHS Data Brief, No 289. Hyattsville, MD: National Center for Health Statistics.; 2017. https://www.cdc.gov/nchs/data/databriefs/db289.pdf.
   Google Scholar
• Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics–2009 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation. 2009;119(3). DOI:10.1161/CIRCULATIONAHA.108.191261
   Google Scholar
• Dahlöf B, Hansson L, Lindholm LH, et al. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet. 1991;338(8778):1281–1285.
   PubMed Web of Science ®Google Scholar
• SHEP Cooperative Study Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension final results of the Systolic Hypertension in the Elderly Program (SHEP). J Am Med Assoc. 1991;265(24):3255–3264.
   Web of Science ®Google Scholar
• Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The systolic hypertension in Europe (Syst-Eur) trial investigators. Lancet. 1997;350(9080):757–764.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens. 1998;16(12, Pte. 1):1823–1829.
   PubMed Web of Science ®Google Scholar
• Beckett N, Peters R, Fletcher A, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–1898.
   PubMed Web of Science ®Google Scholar
• Mancia G. Blood pressure reduction and cardiovascular outcomes: past, present, and future. Am J Cardiol. 2007;100(3):S3-S9.
   Google Scholar
• Veterans Administration Cooperative Study Group. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202(11):1028–1034.
   PubMed Web of Science ®Google Scholar
• Veterans Administration Cooperative Study Group. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213(7):1143–1152.
   PubMed Web of Science ®Google Scholar
• Veterans Administration Cooperative Study Group. Effects of treatment on morbidity in hypertension III. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation. 1972;45(5):991–1004.
   PubMed Web of Science ®Google Scholar
• Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979;242(23): 2562.
   PubMed Web of Science ®Google Scholar
• Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. II. Mortality by race-sex and age. JAMA. 1979;242(23): 2562.
   PubMed Web of Science ®Google Scholar
• Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European working party on high blood pressure in the elderly trial. Lancet. 1985;1(8442):1349–1354.
   PubMed Web of Science ®Google Scholar
• Antikainen R, Jousilahti P, Tuomilehto J. Systolic blood pressure, isolated systolic hypertension and risk of coronary heart disease, strokes, cardiovascular disease and all-cause mortality in the middle-aged population. J Hypertens. 1998;16(5):577–583.
   PubMed Web of Science ®Google Scholar
• Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in elderly: meta- analysis of outcome trials. Lancet. 2000;355:865–872.
   PubMed Web of Science ®Google Scholar
• Langer RD, Criqui MH, Barrett-Connor EL, et al. Blood pressure change and survival after age 75. Hypertension. 1993;22:551–559.
   PubMed Web of Science ®Google Scholar
• Satish S, Freeman DH, Ray L, et al. The relationship between blood pressure and mortality in the oldest old. J Am Geriatr Soc. 2001;49(4):367–374.
   PubMed Web of Science ®Google Scholar
• Gueyffier F, Bulpitt C, Boissel J-P, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet. 1999;353(9155):793–796.
   PubMed Web of Science ®Google Scholar
• Aronow WS. Older age should not be a barrier to the treatment of hypertension. Nat Clin Pract Cardiovasc Med. 2008;5(9):514–515.
   PubMedGoogle Scholar
• Aronow WS. Why and how we should treat elderly patients with hypertension? Curr Vasc Pharmacol. 2010;8(6):780–787.
   PubMed Web of Science ®Google Scholar
• Aronow WS. Treatment of hypertension in the elderly. J Am Med Dir Assoc. 2013;14(11):847.
   PubMed Web of Science ®Google Scholar
• Bejan-Angoulvant T, Saadatian-Elahi M, Wright JM, et al. Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials. J Hypertens. 2010;28(7):1366–1372.
   PubMed Web of Science ®Google Scholar
• Reboldi G, Gentile G, Angeli F, et al. Blood pressure lowering in the oldest old. J Hypertens. 2010;28(7):1373–1376.
   PubMed Web of Science ®Google Scholar
• Schall P, Wehling M. Treatment of arterial hypertension in the very elderly: a meta-analysis of clinical trials. Arzneimittelforschung. 2011;61(04):221–228.
   PubMedGoogle Scholar
• Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet (London, England). 2013;381(9868):752–762.
   PubMed Web of Science ®Google Scholar
• Odden MC, Peralta CA, Haan MN, et al. Rethinking the association of high blood pressure with mortality in elderly adults: the impact of frailty. Arch Intern Med. 2012;172(15):1162–1168.
   PubMedGoogle Scholar
• Wu C, Smit E, Peralta CA, et al. Functional status modifies the association of blood pressure with death in elders: health and retirement study. J Am Geriatr Soc. 2017;65(7):1482–1489.
   PubMed Web of Science ®Google Scholar
• The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–2116.
   PubMed Web of Science ®Google Scholar
• Collaboration PS. 1-s2.0-S0140673602119118-main. 2002;360:1903–1913.
   Google Scholar
• Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351(9118):1755–1762.
   PubMed Web of Science ®Google Scholar
• Ogihara T, Saruta T, Rakugi H, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension. 2010;56(2):196–202.
   PubMed Web of Science ®Google Scholar
• Yano Y, Rakugi H, Bakris GL, et al. On-treatment blood pressure and cardiovascular outcomes in older adults with isolated systolic hypertension. Hypertension. 2017;69(2):220–227.
   PubMed Web of Science ®Google Scholar
• Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–1585.
   PubMed Web of Science ®Google Scholar
• MacMahon S, Neal B, Tzourio C, et al. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033–1041.
   PubMed Web of Science ®Google Scholar
• The SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382(9891): 507–515.
   PubMed Web of Science ®Google Scholar
• Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >/=75 years: A randomized clinical trial. JAMA. 2016;315(24):2673–2682.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Lonn E, Pais P, et al. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med. 2016;374(21):2032–2043.
   PubMed Web of Science ®Google Scholar
• Muntner P, Whelton PK. Using predicted cardiovascular disease risk in conjunction with blood pressure to guide antihypertensive medication treatment. J Am Coll Cardiol. 2017;69(19):2446–2456. .
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the american college of cardiology/american heart association task force on clinical pr. Hypertension. November 2017. DOI:10.1161/HYP.0000000000000065.
   Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–1252.
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105–1187.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang Y, Liu G, et al. The Felodipine Event Reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23(12):2157–2172.
   PubMed Web of Science ®Google Scholar
• Weber MA, Kjeldsen SE, Brunner HR, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363:2045–2051. http://image.thelancet.com/extras/04let5020web.pdf
   Web of Science ®Google Scholar
• Pepine CJ, Kowey PR, Kupfer S, et al. Predictors of adverse outcome among patients with hypertension and coronary artery disease. J Am Coll Cardiol. 2006;47(3):547–551.
   PubMed Web of Science ®Google Scholar
• Turner R, Matthews D, Neil A, et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J. 1998;317:703–713.
   PubMed Web of Science ®Google Scholar
• Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61(3):1086–1097.
   PubMed Web of Science ®Google Scholar
• Estacio RO, Jeffers BW, Gifford N, et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(Suppl 2):B54–64.
   PubMed Web of Science ®Google Scholar
• Arima H, Chalmers J, Woodward M, et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens. 2006;24(6):1201–1208.
   PubMed Web of Science ®Google Scholar
• Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: A report of the American college of cardiology foundation task force on clinical expert consensus documents. J Am Coll Cardiol. 2011;57(20):2037–2114.
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–2219.
   PubMed Web of Science ®Google Scholar
• Hackam DG, Quinn RR, Ravani P, et al. The 2013 Canadian hypertension education program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2013;29(5):528–542.
   PubMed Web of Science ®Google Scholar
• Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the american society of hypertension and the international society of hypertension. J Hypertens. 2014;32(1):3–15.
   PubMed Web of Science ®Google Scholar
• Gibbons GH, Shurin SB, Mensah GA, et al. Refocusing the agenda on cardiovascular guidelines: An announcement from the national heart, lung, and blood institute. J Am Coll Cardiol. 2013;62(15):1396–1398.
   PubMed Web of Science ®Google Scholar
• Gibbons GH, Harold JG, Jessup M, et al. The next steps in developing clinical practice guidelines for prevention. J Am Coll Cardiol. 2013;62(15):1399–1400.
   PubMed Web of Science ®Google Scholar
• James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults. JAMA. 2014;311(5):507.
   PubMed Web of Science ®Google Scholar
• O’Brien E. End of the joint national committee heritage? Hypertension. 2014;63(5):904–906.
   PubMed Web of Science ®Google Scholar
• JATOS study group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008;31(12): 2115–2127.
   PubMed Web of Science ®Google Scholar
• Wright J, Fine LJ, Lackland DT, et al. Evidence supporting a systolic blood pressure goal of less than 150 mmHg in patients aged 60 years or older : the minority view. Ann Intern Med. 2014;14:499–504. DOI:10.7326/M13-2981
   PubMedGoogle Scholar
• Krakoff LR, Gillespie RL, Ferdinand KC, et al. 2014 Hypertension recommendations from the eighth joint national committee panel members raise concerns for elderly black and female populations. J Am Coll Cardiol. 2014;64(4):394–402.
   PubMed Web of Science ®Google Scholar
• Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the american heart association, american college of cardiology, and american society of hypertension. J Am Coll Cardiol. 2015;65(18):1998–2038.
   PubMed Web of Science ®Google Scholar
• Denardo SJ, Gong Y, Nichols WW, et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: An INVEST substudy. Am J Med. 2010;123(8):719–726.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. JAMA. 2004;292(18):2217.
   PubMed Web of Science ®Google Scholar
• Leung AA, Nerenberg K, Daskalopoulou SS, et al. Hypertension Canada’s 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2016;32(5):569–588.
   PubMed Web of Science ®Google Scholar
• Gabb GM, Mangoni AA, Anderson CS, et al. Guideline for the diagnosis and management of hypertension in adults — 2016. Med J Aust. 2016;205(2):85–89.
   PubMed Web of Science ®Google Scholar
• Qaseem A, Wilt TJ, Rich R, et al. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: A clinical practice guideline from the american college of physicians and the american academy of family physicians. Ann Intern Med. 2017;166(6):430–437.
   PubMed Web of Science ®Google Scholar
• Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2014;129(25 suppl 2):S49-S73.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;63(25PART B):2889–2934.
   PubMedGoogle Scholar
• The ALLHAT Officers. Major outcomes in high-risk hypertensive patients randomized to or calcium channel blocker vs diuretic. J Am Med Assoc. 2002;288(23): 2981–2997.
   Web of Science ®Google Scholar
• Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-lines agents. J Am Med Assoc. 1997;277(19):739–745.
   Google Scholar
• Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348(7):583–592.
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–2428.
   PubMed Web of Science ®Google Scholar
• Reboussin DM, Allen NB, Griswold ME, et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2017. DOI:10.1016/j.jacc.2017.11.004.
   PubMed Web of Science ®Google Scholar
• Reubi FC, Cottier PT. Effects of reduced glomerular filtration rate on responsiveness to chlorothiazide and mercurial diuretics. Circulation. 1961;23:200–210.
   PubMed Web of Science ®Google Scholar
• Williams B, Macdonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059–2068.
   PubMed Web of Science ®Google Scholar
• The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23): 1429–1435.
   PubMed Web of Science ®Google Scholar
• The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5): 293–302. .
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3): 145–153.
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart outcomes prevention evaluation study investigators. Lancet (London, England). 2000;355(9200):253–259.
   PubMed Web of Science ®Google Scholar
• Ogedegbe G, Shah NR, Phillips C, et al. Comparative effectiveness of angiotensin-converting enzyme inhibitor-based treatment on cardiovascular outcomes in hypertensive blacks versus whites. J Am Coll Cardiol. 2015;66(11):1224–1233.
   PubMed Web of Science ®Google Scholar
• Leenen FHH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006;48(3):374–384.
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (London, England). 2002;359(9311):995–1003.
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21(5):875–886.
   PubMed Web of Science ®Google Scholar
• Schrader J, Luders S, Kulschewski A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36(6):1218–1226.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559.
   PubMed Web of Science ®Google Scholar
• Granger CB, Mcmurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced lef. Lancet. 2003;362(March 2001):772–776.
   PubMedGoogle Scholar
• Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-preserved trial. Lancet. 2003;362(9386):777–781.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet (London, England). 2008;372(9644):1174–1183.
   PubMed Web of Science ®Google Scholar
• Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. J Am Med Assoc. 1998;279(23):1903–1907.
   PubMed Web of Science ®Google Scholar
• Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses. J Hypertens. 2015;33(7):1321–1341.
   PubMed Web of Science ®Google Scholar
• Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288(3):351–357.
   PubMed Web of Science ®Google Scholar
• Gong L, Zhang W, Zhu Y, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens. 1996;14(10):1237–1245.
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805–2816.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Calvo C, Mockel V, et al. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Press. 2007;16(6):381–391.
   PubMed Web of Science ®Google Scholar
• Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke. 2014;45(7):2160–2236.
   PubMed Web of Science ®Google Scholar
• Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049–2057.
   PubMed Web of Science ®Google Scholar
• Aronow WS. Lifestyle measures for treating hypertension. Arch Med Sci. 2017;13(5):1241–1243.
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C. Association of postprandial hypotension with incidence of falls, syncope, coronary events, stroke, and total mortality at 29-month follow-up in 499 older nursing home residents. J Am Geriatr Soc. 1997;45(9):1051–1053.
   PubMed Web of Science ®Google Scholar